FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis

Nature Communications

Volumn 6, Issue , 2015, Pages

  Perry, Rachel J ^a   Lee, Sangwon ^a   Ma, Lie ^a   Zhang, Dongyan ^a   Schlessinger, Joseph ^a   Shulman, Gerald I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A; CORTICOSTERONE; CORTICOTROPIN; PYRUVATE CARBOXYLASE; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 1; RECOMBINANT FIBROBLAST GROWTH FACTOR 19; UNCLASSIFIED DRUG; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; GLUCOSE; INSULIN;

DIABETES; ENZYME ACTIVITY; METABOLISM; PLASMA; RODENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; ENZYME ACTIVITY; EXPERIMENTAL MODEL; GLUCONEOGENESIS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN DEPENDENT DIABETES MELLITUS; LIPOLYSIS; NONHUMAN; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LIVER; MALE; METABOLISM; SPRAGUE DAWLEY RAT;

RATTUS; RODENTIA;

ACETYL COENZYME A; ADRENOCORTICOTROPIC HORMONE; ANIMALS; CORTICOSTERONE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTORS; GLUCOSE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INJECTIONS, INTRAVENTRICULAR; INSULIN; LIPOLYSIS; LIVER; MALE; PITUITARY-ADRENAL SYSTEM; PYRUVATE CARBOXYLASE; RATS, SPRAGUE-DAWLEY;

EID: 84928790920     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7980     Document Type: Article

References (22)

1. Morton, G. J. et al. FGF19 action in the brain induces insulin-independent glucose lowering. J. Clin. Invest. 123, 4799-4808 (2013).
2. Ryan, K. K. et al. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 154, 9-15 (2013).
3. Marcelin, G. et al. Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism. Mol. Mech. 3, 19-28 (2014).
4. Suh, J. M. et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature 513, 436-439 (2014).
5. Jones, S. Mini-review: endocrine actions of fibroblast growth factor 19. Mol. Pharm. 5, 42-48 (2008).
6. Katoh, M. & Katoh, M. Evolutionary conservation of CCND1-ORAOV1- FGF19-FGF4 locus from zebrafish to human. Int. J. Mol. Med. 12, 45-50 (2003).
7. McWhirter, J. R., Goulding, M., Weiner, J. A., Chun, J. & Murre, C. A novel fibroblast growth factor gene expressed in the developing nervous system is a downstream target of the chimeric homeodomain oncoprotein E2A-Pbx1. Development 124, 3221-3232 (1997).
8. Fu, L. et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145, 2594-2603 (2004).
9. Tomlinson, E. et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143, 1741-1747 (2002).
10. Kir, S. et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331, 1621-1624 (2011).
11. Zakrzewska, M., Marcinkowska, E. & Wiedlocha, A. FGF-1: from biology through engineering to potential medical applications. Crit. Rev. Clin. Lab. Sci. 45, 91-135 (2008).
12. Jonker, J. W. et al. A PPARgamma-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 485, 391-394 (2012).
13. Perry, R. J. et al. Leptin reverses diabetes by suppression of the hypothalamicpituitary- adrenal axis. Nat. Med. 20, 759-763 (2014).
14. Scrutton, M. C., Keech, D. B. & Utter, M. F. Pyruvate carboxylase. Iv. partial reactions and the locus of activation by acetyl coenzyme A. J. Biol. Chem. 240, 574-581 (1965).
15. Strack, A. M., Sebastian, R. J., Schwartz, M. W. & Dallman, M. F. Glucocorticoids and insulin: reciprocal signals for energy balance. Am. J. Physiol. 268, R142-R149 (1995).
16. Schwartz, M. W., Strack, A. M. & Dallman, M. F. Evidence that elevated plasma corticosterone levels are the cause of reduced hypothalamic corticotrophin-releasing hormone gene expression in diabetes. Regul. Pept. 72, 105-112 (1997).
17. Goetz, R. et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell Biol. 27, 3417-3428 (2007).
18. Jornayvaz, F. R. et al. Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. Proc. Natl Acad. Sci. USA 108, 5748-5752 (2011).
19. Neschen, S. et al. Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. Cell Metab. 2, 55-65 (2005).
20. Vatner, D. F. et al. Thyroid hormone receptor-beta agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways. Am. J. Physiol. Endocrinol. Metab. 305, E89-100 (2013).
21. Passonneau, J. V. & Rottenberg, D. A. An assessment of methods for measuremennt of glycogen synthetase activity including a new direct one-step assay. Anal. Biochem. 51, 528-541 (1973).
22. Zhang, D. et al. Resistance to high-fat diet-induced obesity and insulin resistance in mice with very long-chain acyl-CoA dehydrogenase deficiency. Cell Metab. 11, 402-411 (2010).